FOUR TRENDS RESHAPING THE ACTIVE PHARMACEUTICAL INGREDIENT INDUSTRY IN 2026

For most of the past two decades, API manufacturing economics were largely driven by cost optimization, favoring geographies with structurally lower production costs. China and, increasingly, India became critical sourcing hubs for key starting materials (KSMs), intermediates, and finished APIs, while pharmaceutical manufacturing capacity across Western markets contracted. This model optimized near-term cost efficiency but also increased dependence on concentrated global supply chains.

That cost-centric model is now being reassessed as supply security becomes a strategic priority. A 2025 U.S. executive order directed federal agencies to establish a Strategic Active Pharmaceutical Ingredients Reserve (SAPIR), targeting a six-month domestic supply of APIs for approximately 26 medicines considered critical to national health and security. The Section 232 tariff deadline of July 31, 2026, has further increased the pressure on branded manufacturers to evaluate domestic production commitments or face potentially significant import duties. At the same time, the FDA’s new PreCheck pilot is creating an additional incentive for sponsors developing qualifying domestic manufacturing capacity by enabling earlier regulatory engagement.

Capital allocation increasingly reflects this shift from cost efficiency toward supply resilience. Eli Lilly has committed more than USD 6 billion to a new API manufacturing campus in Huntsville, Alabama, while AbbVie is investing USD 195 million to expand domestic API production at its North Chicago, Illinois facility. Together with other reshoring initiatives, these investments contributed to more than USD 480 billion in announced U.S. pharmaceutical manufacturing commitments by mid-2026. The scale of these commitments indicates that supply-chain localization is moving beyond a risk-mitigation measure toward a longer-term strategic investment theme.

However, focusing solely on API localization may provide only partial resilience. Charlie Lyon, vice president of manufacturing, procurement, and logistics at the API Innovation Center, highlights a critical structural dependency: APIs themselves rely on specialty and fine chemicals that have undergone a similar shift toward offshore production. Consequently, domestic API capacity without corresponding localization of upstream KSM and intermediate production may reduce visibility into supply risk without fundamentally eliminating it. The emerging challenge, therefore, is not simply to reshore APIs, but to determine how much the upstream pharmaceutical value chain needs to be localized to achieve meaningful supply security.

The key shift is not only where APIs are manufactured, but also what constitutes an increasingly strategic API. Conventional small-molecule synthesis continues to account for the majority of volumes, but a growing proportion of industry investment is moving toward more complex and technically demanding molecules. This includes highly potent APIs (HPAPIs), cytotoxic payloads and linkers used in antibody-drug conjugates (ADCs), and peptide APIs underpinning the rapidly expanding GLP-1 class of obesity and diabetes therapies.

This transition is reshaping capacity requirements and raising the technical barriers to API manufacturing. HPAPI and ADC production, in particular, require specialized containment, handling, analytical capabilities, and highly controlled manufacturing environments, creating a stronger case for dedicated capacity. Olon, for instance, has added new occupational exposure band (OEB) 5 production lines alongside a state-of-the-art OEB 6 facility focused on ultra-potent ADC payloads and payload-linkers. Piramal Pharma Solutions is investing $90 million to expand its ADC manufacturing footprint, including HPAPI payload-linker production in Michigan and ADC fill-finish capacity in Kentucky. Meanwhile, Lonza’s dedicated HPAPI2 facility in Visp, Switzerland reached full commercial operations in 2025, alongside continued investment in its bioconjugation capabilities.

Collectively, these investments indicate that API manufacturing is evolving from a predominantly scale- and cost-driven business toward one increasingly differentiated by technical complexity, containment requirements, and specialized manufacturing capabilities.

According to Ester Masllorens, senior vice president of global R&D at Olon

The growing complexity and potency of these molecules, she notes, requires sophisticated containment capabilities and manufacturing strategies that go well beyond conventional small-molecule production.

Peptide APIs have moved just as fast, propelled almost entirely by GLP-1 receptor agonists. Samsung Biologics has a pending $1.8 billion acquisition of peptide CDMO PolyPeptide Group, CordenPharma acquired US-based peptide manufacturer AmbioPharm to add domestic solid-phase peptide synthesis (SPPS) capacity, and peptide-focused CDMOs collectively committed more than $2.4 billion to new capacity in 2026 alone. Franco Stevanato, chief executive of Stevanato Group, told analysts that for the next decade, reflecting a broad preparation of the supply chain across drug substance and drug product manufacturing alike.

A third structural shift cuts across molecule classes: the gradual transition from conventional batch-based manufacturing toward continuous processing, in-line analytics, and artificial intelligence-enabled process development. Technologies such as continuous and telescoped multistep synthesis, which have been discussed extensively for years, are increasingly moving beyond pilot-scale demonstrations into commercial production. This transition is being enabled by advances in flow chemistry, process analytical technology (PAT), and digital twins, allowing manufacturers to monitor critical process parameters and product quality in real time rather than relying predominantly on offline, end-of-batch testing.

The implications extend beyond conventional small-molecule drug substance manufacturing. Continuous and digitally enabled process architectures are increasingly being evaluated across more complex production environments, where tighter process control, reduced variability, and improved resource utilization can have a direct impact on manufacturing economics and scalability. At DCAT Week, Russell Miller, vice president of global sales and marketing at Enzene, argued that reshaping biologics production as much as small-molecule API synthesis, given the multi-week timelines involved in mammalian cell-culture processes and the efficiency gains that continuous operation can unlock.

Artificial intelligence is increasingly being integrated into this manufacturing transition rather than viewed as a substitute for it. At CPHI Milan 2026, Andrew Parker, executive drug development consultant at Quotient Sciences, a CRDMO, characterized AI adoption in formulation science as being at an early stage, with the technology primarily serving to augment, rather than replace, formulators’ expertise. AI is being used to accelerate design-of-experiments activities, improve formulation optimization, and enable teams to reach target product profiles more efficiently, while human-in-the-loop assessment remains critical to decision-making. Across API manufacturing, similar applications are emerging in reaction optimization, automated visual assessment of crystallization and particle characteristics, and the selection of catalysts and solvents.

Regulatory engagement is also evolving in parallel with these manufacturing advances. The FDA’s Emerging Technology Program continues to engage with sponsors implementing continuous manufacturing technologies, while the agency’s new PreCheck pilot provides phased technical guidance and earlier pre-submission engagement for qualifying API and drug-substance manufacturing projects. The initial cohort includes projects spanning sterile injectables, APIs, advanced biologics, and gene-therapy manufacturing, indicating a broader regulatory focus on supporting the adoption of emerging manufacturing technologies.

The fourth trend reflects a fundamental change in when and why sustainability considerations are incorporated into API process design. Historically, green chemistry principles such as solvent reduction, improved atom economy, and waste minimization were often evaluated later in the development cycle, once a commercial manufacturing route had been substantially established. Increasingly, these principles are being embedded into route selection from the outset, supported by evolving regulatory expectations, cost pressures, and greater technological maturity.

Biocatalysis is emerging as a key enabler of this transition. Enzymatic synthesis, once constrained by limited substrate specificity and challenges around process stability, has evolved into a more commercially viable manufacturing approach, supported by advances in enzyme engineering, directed evolution, and computational protein design. Biocatalytic processes can often operate under milder temperature and pressure conditions and use water-based reaction systems, while generating lower waste per kilogram of API than several conventional metal-catalyzed approaches. This can reduce both environmental impact and the downstream purification requirements associated with API production.

Solvent management remains one of the most significant opportunities for improving process sustainability, given that solvents can account for 80.0% to 90.0% of the total mass used in pharmaceutical synthesis. Greater adoption of optimized solvent selection, solvent recovery through distillation, and continuous-flow processing can materially reduce process mass intensity without changing the underlying drug substance. Industry process-engineering estimates suggest that these interventions can potentially reduce process mass intensity by 40.0% to 60.0%, depending on the chemistry and manufacturing configuration.

The shift is also increasingly reflected in CDMO investment and capacity strategies. Olon’s latest HPAPI and ADC facility, for example, combines ultra-high containment with flow chemistry, photochemistry, biocatalysis, and tangential flow filtration to support safer, more resource-efficient, and scalable manufacturing. Industry events are reinforcing the same direction of travel. CPHI Milan 2026 is introducing a dedicated Sustainability Summit during the first two days of the event, with event director Tara Dougal positioning the initiative as an effort to move the industry dialogue beyond broad sustainability ambitions toward practical and actionable interventions across the pharmaceutical supply chain.

Active pharmaceutical ingredient manufacturing in 2026 is being reshaped by a fundamental change in what the industry optimizes for.

The sector is moving from lowest-cost sourcing toward resilient, geographically diversified supply chains, from predominantly conventional small-molecule synthesis toward a portfolio increasingly built around HPAPIs, ADCs, and peptides, from batch manufacturing toward continuous, digitally monitored, AI-assisted process design, and from sustainability as an afterthought toward green chemistry as a core design criterion.

The emergence of onshoring investment, ultra-high-containment facilities, large-scale peptide synthesis capacity, continuous flow platforms, and biocatalytic routes is expanding the industry’s manufacturing toolkit across generics, innovator small molecules, and complex modalities alike.

At the same time, the definition of a well-run API supply chain is becoming broader. Manufacturers and their customers are increasingly weighing geographic resilience, molecular complexity, digital process control, and environmental footprint alongside the traditional benchmarks of cost, yield, and regulatory compliance.